Cancer Profiling and Pathways: Technologies and Global Markets

Published - Jan 2014| Analyst - Usha Nagavarapu| Code - BIO073B
Market Research Report Single User License: $2750 Member Price: FREE

Report Highlights

The global market for cancer profiling technologies reached $26.1 billion in 2012. This market is expected to grow to nearly $30.1 billion in 2013 and $54.8 billion in 2018, a compound annual growth rate (CAGR) of 12.8% over the five-year period, 2013 to 2018.

Report Includes

  • An overview of the global market for cancer profiling and biomarker studies
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
  • Discussion of products in this market, cancer markets in newly emerging tools, diagnostics and therapeutics, and their impacts on the market
  • Examination of evolving methods, such as microarray analysis, multiplex PCR, and quantitative real-time PCR, which are integral to deciphering the molecular mechanisms involved in gene function, biological development, and disease progression, and are important tools in the discovery and development of new drug targets and diagnostic biomarkers
  • Identifications of important cancer profiling techniques, market share by type of products on the market and market share by company, as well as types of cancers and biomarkers
  • Coverage of epigenetic, methylation, and miRNA products in development, products in clinical trials, and currently marketed and clinical-stage development products
  • Comprehensive company profiles of key players in the market.

Report Scope

Cancer biomarkers have gained significant importance in the drug-development process, and the market is an emerging segment. To gain an understanding of the market dynamics, market size and competitive landscape, a detailed analysis of cancer biomarker market and cancer profiling technologies and new developments is needed. Microarray technologies provide analysis of tens of thousands of molecules for a variety of assays, including drug binding, molecular interactions, enzyme activity and pathway identification. These microarrays, which include DNA microarrays, protein microarrays, tissue microarrays, low complexity microarrays and carbohydrate microarrays, are excellent tools for gene expression profiling, biomarker profiling and diagnostics.

Pharmaceutical and biotechnology researchers use microarrays to streamline drug target identification, selection, validation and predictive testing. Rapid growth in the clinical research and diagnostic devices markets holds great potential for applications of microarray technology, including basic research, clinical trials and diagnostic devices. This report examines various microarray platforms and the technologies that are utilized to detect DNA and proteins for the purpose of drug discovery, disease diagnosis and disease monitoring. This report also examines companies that are actively developing and marketing microarray instrumentation or microarray biochips.

The report categorizes the biomarkers and profiling market and provides market data, market drivers, trends and opportunities, top-selling products, key players and competitive outlook. This report will also provide market tables and also provides company profiles.

This report analyzes the cancer profiling and pathways market: technologies market, tools market, and application market (diagnosis, drug development and discovery). This report also looks into recent studies, microRNA detection and profiling, clinically oriented microRNA profiling in several human cancers. The report covers epigenetic, methylation and miRNA products in development, products in clinical trials, currently marketed and clinical-stage development products. Relationship between miRNAs and epigenetics is also examined. This report categorizes the market for epigenetics, forecasting the market value in revenue by analyzing the current and future trends in research, diagnostics and therapeutics industries. This report also looks at SNPs analysis instruments, reagents, software and services, providing information critical to understanding the business behind this new technology.

The following technologies and segments are excluded from this report:  detailed instruments, pharmacogenomics, combinatorial chemistry, biochip, bioinformatics and high-throughput screening (HTS). Uses of emerging technologies in drug discovery such as lab-on-a-chip (LOAC), nanotechnology, and RNA interference (RNAi) also are not discussed here.

Analyst Credentials

Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience.  She has managed preclinical discovery programs from target identification, including IND enabling studies, and assisted out-licensing and portfolio development activities.  Her strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early startups to fulfill operational obligations while minimizing overall operational cost and burden.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Sep-2010| Analyst - Usha Nagavarapu| Code - BIO073A

Report Highlights

  • BCC estimates the global market for Cancer Profiling Technologies at about $15 billion in 2009.  BCC expects the market to reach $17.7 billion in 2010 and $47 billion by 2015, at a compound annual growth rate (CAGR) of 21.6% over the next 5 years.
  • Proteomics were worth $7.9 billion in 2009. This segment is expected to increase to $9.4 billion in 2010 and reach $19.5 billion by 2015, at a compound annual growth rate (CAGR) of 15.6%. 
  • Genomics were the second-largest application segment, with nearly $6 billion in 2009.  While remaining the second-largest market segment, its share of the global market is expected to increase to a $10.5 billion by 2015.
  • Epigenetics/methylation and microRNA are the other two products where former being the third largest with expected percentage of $17 billion by 2015 and latter being the last with $98.1 million by 2015.
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report